Evaxion announces closing of $15 million public offering

Copenhagen, denmark, feb. 06, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced the closing on february 5, 2024 of its previously announced public offering of 3,750,000 of its american depositary shares (“adss”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 adss at a combined public offering price of $4.00 per ads (or pre-funded warrant in lieu thereof) and accompanying warrant. msd global health innovation fund (msd ghi), a corporate venture capital arm of merck & co., inc., rahway, nj, usa, who became an evaxion shareholder in december 2023, participated in this offering. the warrants have an exercise price of $4.00 per ads, are exercisable immediately upon issuance and will expire five years following the date of issuance. each ads represents ten ordinary shares of the company.
EVAX Ratings Summary
EVAX Quant Ranking